Axsome Therapeutics Inc Stock
€186.35
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Axsome
sharewise wants to provide you with the best news and tools for Axsome, so we directly link to the best financial data sources.
Financials
News
Axsome Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Axsome Therapeutics, Inc.? Here are five stocks we like better.
- Q2 revenue rose 46% year over year to $218 million, led by AUVELITY sales of $180.3 million, while the
Compass Pathways Q2 Earnings Call Highlights
Key Points
- Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better.
- Compass Pathways remains on track to file for FDA approval of COMP360 for treatment-resistant
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
Key Points
- Interested in Axsome Therapeutics, Inc.? Here are five stocks we like better.
- Axsome Therapeutics said it is on track to launch Auvelity for Alzheimer’s disease agitation this
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does
Even with recent geopolitical tensions and macroeconomic challenges, broader equities have performed fairly well this year. But how long will that last? Perhaps these headwinds will, eventually
3 Under-the-Radar Stocks to Buy and Hold
A relatively small group of companies capture much of Wall Street's attention and disproportionately affects the performance of major indexes like the S&P 500. It's not surprising, then, that many
Better Growth Buy: Axsome vs Revolution Medicines
Axsome Therapeutics (NASDAQ: AXSM) and Revolution Medicines (NASDAQ: RVMD) have offered investors significant growth so far this year. The biotech companies saw their shares soar 34% and 135%
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.
Axsome Therapeutics (NASDAQ: AXSM) has been going through a particularly significant growth phase in recent years, launching drugs for central nervous system (CNS) conditions and pushing several
3 Under-the-Radar Stocks to Buy and Hold for a Decade
It isn't only the most popular stocks that deliver strong returns. There are plenty of little-known corporations with attractive prospects that can be great additions to a well-diversified portfolio
3 Overlooked Stocks Set to Soar in 2026
Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors.
Axsome Therapeutics (NASDAQ: AXSM) is a mid-cap with
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
Shares of Axsome Therapeutics (NASDAQ: AXSM) have been on a tear, and that just accelerated today. After soaring more than 20% last month, shares of the biopharmaceutical company jumped another
Why Axsome Therapeutics Stock Jumped Over 20% in April
Axsome Therapeutics (NASDAQ: AXSM) has been growing sales rapidly with its Auvelity antidepressant. The biopharmaceutical company focuses on developing therapies for central nervous system (CNS)
Is This Healthcare Stock a Millionaire Maker?
Axsome Therapeutics (NASDAQ: AXSM), a midcap biotech, went public in 2015. Since then, the stock has delivered market-beating returns thanks to significant clinical and regulatory progress, as well
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Summit Therapeutics (NASDAQ: SMMT) has grown in prominence over the past three years, moving from a small-cap biotech to a large-cap valuation, driven by regulatory progress for its leading
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics (NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter.
According to a
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision
Herriot Tabuteau, CEO of Axsome Therapeutics (NASDAQ:AXSM), exercised and immediately sold 32,410 common shares in an open-market transaction on February 2, 2026, as disclosed in the SEC Form 4
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036
Axsome Therapeutics (NASDAQ: AXSM) isn't one of the more famous or prominent biotech companies, but investors interested in the industry had better get to know this drugmaker. Not only has Axsome